Sales Focus for Oasmia

Last week, Oasmia Pharmaceuticals reported a slight increase in losses in the fourth quarter of 2015. Looking ahead, product sales will be a key issue while the company finds itself in the midst of partnership discussions over its XR17 platform. “The platform provides a solution to an immense difficulty in the industry.”, says Chairman Julian Aleksov, a statement supported by Executive Vice President Anders Blom.Upon receiving the good news about the approval of Paclical in Russia, investors expected a rapid inflow of cash for Oasmia Pharmaceuticals. But expectations were not met. The